Alemtuzumab
| Alemtuzumab | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Alemtuzumab is a monoclonal antibody used in the treatment of multiple sclerosis and certain types of leukemia, such as chronic lymphocytic leukemia (CLL). It targets the CD52 antigen, a protein present on the surface of mature lymphocytes.
Mechanism of Action[edit]
Alemtuzumab works by binding to the CD52 antigen on the surface of B cells and T cells. This binding triggers the destruction of these cells by the immune system, primarily through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). By depleting these lymphocytes, alemtuzumab modulates the immune system, which is beneficial in conditions like multiple sclerosis and leukemia.
Medical Uses[edit]
Alemtuzumab is primarily used in the treatment of:
- Multiple sclerosis: It is used to reduce the frequency of relapses and delay the progression of disability in patients with relapsing forms of the disease.
- Chronic lymphocytic leukemia (CLL): It is used in patients who have been treated with other therapies without success.
Administration[edit]
Alemtuzumab is administered via intravenous infusion. The dosing regimen varies depending on the condition being treated. For multiple sclerosis, it is typically given in two courses, with the first course consisting of daily infusions for five consecutive days, and the second course given a year later for three consecutive days.
Side Effects[edit]
Common side effects of alemtuzumab include:
- Infusion reactions such as rash, headache, and fever
- Increased risk of infections due to immunosuppression
- Autoimmune conditions, such as thyroid disorders and immune thrombocytopenic purpura (ITP)
History[edit]
Alemtuzumab was originally developed as a treatment for leukemia. It was later found to be effective in treating multiple sclerosis, leading to its approval for this indication. The drug was initially marketed under the brand name Campath for leukemia and later as Lemtrada for multiple sclerosis.
Related pages[edit]
Alemtuzumab[edit]
-
Alemtuzumab
Alemtuzumab[edit]
-
Alemtuzumab
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
